Impact of Sex Hormones on Human Skin Immunity in Health and Hidradenitis Suppurativa (SIAP)

NCT ID: NCT07291193

Last Updated: 2026-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2031-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sex hormones are major regulators of skin immunity. Pregnancy represents a unique physiological state of profound hormonal remodeling. In late pregnancy, maternal levels of estrogens, progesterone, and other hormones increase dramatically, offering an unparalleled model to study the impact of sex hormones on skin immunity. Hidradenitis suppurativa (HS) provides a clinically relevant model to examine how sex hormones modulate skin inflammation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sex hormones are major regulators of skin immunity. Recent work from Belkaid's laboratory in mice demonstrated that testosterone negatively regulated skin innate lymphoid cells (ILC2), leading to a reduction in dendritic cell accumulation and decreased activation in males, along with reduced tissue immunity. These findings highlight that sex-related differences in skin immunity emerge primarily after sexual maturation, driven by fluctuating hormone levels. However, whether these mechanisms are conserved in humans remains unknown.

Pregnancy represents a unique physiological state of profound hormonal remodeling. In late pregnancy, maternal levels of estrogens, progesterone, and other hormones increase dramatically, offering an unparalleled model to study the impact of sex hormones on skin immunity. Understanding maternal skin immunity is of particular importance, as the maternal immune system must balance tolerance to the fetus with protection against pathogens. Perturbation in this balance can have lasting effects on both maternal and child health. Faced with the dramatic increase in inflammatory and autoimmune disorders affecting children globally, understanding maternal immunity is of fundamental importance.

Hidradenitis suppurativa (HS) provides a clinically relevant disease model to examine how sex hormones modulate skin inflammation. HS is a chronic inflammatory skin disease with strong sex dimorphism: it affects predominantly women (70%) in Europe but is often more severe in men. In women, HS severity varies with the menstrual cycle and is frequently altered during pregnancy, suggesting a hormonal component in disease modulation. Yet, the mechanisms linking sex hormones, pregnancy, and skin immune responses in HS remain unexplored.

By systematically comparing men, non-pregnant women, and pregnant women, in both health and HS, this study will map immune cell populations in the skin and determine how sex hormones; testosterone, estrogens, and progesterone; shape cutaneous immunity at steady state and during inflammation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Immunity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy - Pregnant women

Adult woman, not affected by Hidradenitis Suppurativa, pregnant in her third trimester

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Healthy - Non-pregnant women

Adult woman, not affected by Hidradenitis Suppurativa

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Healthy - Men

Adult men, not affected by Hidradenitis Suppurativa

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Hidradenitis suppurativa - Pregnant women

Adult woman, affected by Hidradenitis Suppurativa, pregnant in her third trimester

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Hidradenitis suppurativa - Non-pregnant women

Adult woman, affected by Hidradenitis Suppurativa

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Hidradenitis suppurativa - Men

Adult men, affected by Hidradenitis Suppurativa

Blood sample, skin microbiota and biopsy

Intervention Type PROCEDURE

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample, skin microbiota and biopsy

Blood sample (maximum 40mL) Skin microbiota (collection of cells from the skin surface using a swab (non-invasive) Skin biopsy, in hormone-dependent areas and/or in a non-hormone-dependent areas

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Common criteria :
* Subject\>18 years and \<45 years,
* Written informed consent of the subject,
* Subject affiliated to the Assurance Maladie (French Health System) except Aide Médicale d'Etat (French State Medical Aid),
* Subject agrees that genomic analyses may be carried out on the samples
* Specific criteria :
* For pregnant women:Third trimester of pregnancy (between 29-37 weeks of amenorrhea).
* For HS subjects: Subject with hidradenitis suppurativa lesions at the sampling sites.

Exclusion Criteria

* Common criteria :
* Subject immunocompromised,
* Subject under legal protection (guardianship or curatorship),
* Subject is unable to provide informed consent and to comply with the study requirements due to geographical, social, or psychiatric reasons,
* Subject in other research whose procedures may influence the immune system,
* Contraindication to any of medications listed in section 5.1 (antiseptic and local anesthetic used for biopsy(ies)),
* Subject whose health condition does not permit participation in study procedures.
* Specific criteria :
* For no HS subjects : Scarred skin at the biopsy site, Subject with pre-existing and/or still active inflammatory skin conditions, Subject experiencing early menopause (women) or andropause (men).
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Pasteur

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bénédicte OULES, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clarisse GANIER, PhD

Role: CONTACT

0145688767 ext. +33

Julia ABAD

Role: CONTACT

0140669760 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00923-46

Identifier Type: OTHER

Identifier Source: secondary_id

2024-072

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immunopathogenesis of Chlamydia
NCT00607659 COMPLETED